WO2013135737A1 - Compositions for dysphagia assessment - Google Patents
Compositions for dysphagia assessment Download PDFInfo
- Publication number
- WO2013135737A1 WO2013135737A1 PCT/EP2013/055064 EP2013055064W WO2013135737A1 WO 2013135737 A1 WO2013135737 A1 WO 2013135737A1 EP 2013055064 W EP2013055064 W EP 2013055064W WO 2013135737 A1 WO2013135737 A1 WO 2013135737A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- agent
- group
- swallowing
- dysphagia
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 121
- 208000019505 Deglutition disease Diseases 0.000 title claims abstract description 23
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 claims abstract description 75
- 239000002872 contrast media Substances 0.000 claims abstract description 48
- 239000007788 liquid Substances 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 26
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 claims abstract description 20
- 230000009747 swallowing Effects 0.000 claims abstract description 18
- 238000003384 imaging method Methods 0.000 claims abstract description 17
- 238000003745 diagnosis Methods 0.000 claims abstract description 11
- 238000002156 mixing Methods 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims description 43
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 31
- 229940069428 antacid Drugs 0.000 claims description 22
- 239000003159 antacid agent Substances 0.000 claims description 22
- 230000002026 carminative effect Effects 0.000 claims description 20
- 239000006185 dispersion Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 18
- 230000001458 anti-acid effect Effects 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 18
- -1 labeprazole Chemical compound 0.000 claims description 17
- 239000002325 prokinetic agent Substances 0.000 claims description 17
- 229920001353 Dextrin Polymers 0.000 claims description 14
- 239000000796 flavoring agent Substances 0.000 claims description 14
- 239000000416 hydrocolloid Substances 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 14
- 150000005846 sugar alcohols Polymers 0.000 claims description 14
- 229920001285 xanthan gum Polymers 0.000 claims description 14
- 229920002774 Maltodextrin Polymers 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 230000001954 sterilising effect Effects 0.000 claims description 12
- 239000005913 Maltodextrin Substances 0.000 claims description 11
- 235000011187 glycerol Nutrition 0.000 claims description 11
- 229940035034 maltodextrin Drugs 0.000 claims description 11
- 238000004659 sterilization and disinfection Methods 0.000 claims description 11
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 10
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 claims description 10
- 229960001253 domperidone Drugs 0.000 claims description 10
- 235000010493 xanthan gum Nutrition 0.000 claims description 10
- 239000000230 xanthan gum Substances 0.000 claims description 10
- 229940082509 xanthan gum Drugs 0.000 claims description 10
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical group O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 claims description 9
- 229940083037 simethicone Drugs 0.000 claims description 9
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 8
- 235000013355 food flavoring agent Nutrition 0.000 claims description 8
- 235000003599 food sweetener Nutrition 0.000 claims description 8
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 8
- 235000010981 methylcellulose Nutrition 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 8
- 239000003381 stabilizer Substances 0.000 claims description 8
- 239000003765 sweetening agent Substances 0.000 claims description 8
- 244000303965 Cyamopsis psoralioides Species 0.000 claims description 7
- 235000019425 dextrin Nutrition 0.000 claims description 7
- FYGDTMLNYKFZSV-MRCIVHHJSA-N dextrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](CO)OC(O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-MRCIVHHJSA-N 0.000 claims description 7
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims description 7
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 6
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 6
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 235000010980 cellulose Nutrition 0.000 claims description 6
- 229910052748 manganese Inorganic materials 0.000 claims description 6
- 239000011572 manganese Substances 0.000 claims description 6
- 229920002907 Guar gum Polymers 0.000 claims description 5
- 229920000161 Locust bean gum Polymers 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- MJIHNNLFOKEZEW-RUZDIDTESA-N dexlansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-RUZDIDTESA-N 0.000 claims description 5
- 235000010417 guar gum Nutrition 0.000 claims description 5
- 239000000665 guar gum Substances 0.000 claims description 5
- 229960002154 guar gum Drugs 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 claims description 4
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 4
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims description 4
- 244000215068 Acacia senegal Species 0.000 claims description 4
- 235000006491 Acacia senegal Nutrition 0.000 claims description 4
- 241000206575 Chondrus crispus Species 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-ZXXMMSQZSA-N D-iditol Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-ZXXMMSQZSA-N 0.000 claims description 4
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-threitol Chemical compound OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 claims description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- 229920000926 Galactomannan Polymers 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 229920000084 Gum arabic Polymers 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 235000010489 acacia gum Nutrition 0.000 claims description 4
- 229940071162 caseinate Drugs 0.000 claims description 4
- 229960005132 cisapride Drugs 0.000 claims description 4
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 claims description 4
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 claims description 4
- 229960003568 dexlansoprazole Drugs 0.000 claims description 4
- 239000008393 encapsulating agent Substances 0.000 claims description 4
- 229960003276 erythromycin Drugs 0.000 claims description 4
- 229960004770 esomeprazole Drugs 0.000 claims description 4
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 239000000905 isomalt Substances 0.000 claims description 4
- 235000010439 isomalt Nutrition 0.000 claims description 4
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 4
- 229960003174 lansoprazole Drugs 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 229960000381 omeprazole Drugs 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 239000001814 pectin Substances 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 229950003039 renzapride Drugs 0.000 claims description 4
- GZSKEXSLDPEFPT-IINYFYTJSA-N renzapride Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)N[C@H]1[C@H](C2)CCC[N@]2CC1 GZSKEXSLDPEFPT-IINYFYTJSA-N 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 235000010491 tara gum Nutrition 0.000 claims description 4
- 239000000213 tara gum Substances 0.000 claims description 4
- FEBUJFMRSBAMES-UHFFFAOYSA-N 2-[(2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-phosphanyloxan-4-yl]oxy}-3,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-4-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl phosphinite Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 claims description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- 229920001817 Agar Polymers 0.000 claims description 3
- 235000017399 Caesalpinia tinctoria Nutrition 0.000 claims description 3
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 3
- SKCKOFZKJLZSFA-UHFFFAOYSA-N L-Gulomethylit Natural products CC(O)C(O)C(O)C(O)CO SKCKOFZKJLZSFA-UHFFFAOYSA-N 0.000 claims description 3
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 claims description 3
- 229920002305 Schizophyllan Polymers 0.000 claims description 3
- 241000388430 Tara Species 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- 229940072056 alginate Drugs 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- RIMGDBZXWSGBQN-UHFFFAOYSA-N burimamide Chemical compound CNC(=S)NCCCCC1=CN=C[N]1 RIMGDBZXWSGBQN-UHFFFAOYSA-N 0.000 claims description 3
- 229960001380 cimetidine Drugs 0.000 claims description 3
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims description 3
- 239000004927 clay Substances 0.000 claims description 3
- SKCKOFZKJLZSFA-FSIIMWSLSA-N fucitol Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO SKCKOFZKJLZSFA-FSIIMWSLSA-N 0.000 claims description 3
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 239000011630 iodine Substances 0.000 claims description 3
- 159000000014 iron salts Chemical class 0.000 claims description 3
- 229950010386 mitemcinal Drugs 0.000 claims description 3
- BELMMAAWNYFCGF-PZXAHSFZSA-N mitemcinal Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@](C(=O)[C@@H](C)C2=C(C)C[C@](O2)(C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C(C)C)O)[C@H]1C)(C)OC)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 BELMMAAWNYFCGF-PZXAHSFZSA-N 0.000 claims description 3
- 229930014626 natural product Natural products 0.000 claims description 3
- WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 claims description 3
- 229960001217 perflubron Drugs 0.000 claims description 3
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 claims description 3
- IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical compound C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 claims description 3
- 229960002876 tegaserod Drugs 0.000 claims description 3
- 239000004386 Erythritol Substances 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 2
- 235000019414 erythritol Nutrition 0.000 claims description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 2
- 229940009714 erythritol Drugs 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 238000009472 formulation Methods 0.000 abstract description 23
- 239000000843 powder Substances 0.000 abstract description 10
- 235000013305 food Nutrition 0.000 abstract description 9
- 229940039231 contrast media Drugs 0.000 abstract description 5
- 235000005911 diet Nutrition 0.000 abstract description 4
- 230000002159 abnormal effect Effects 0.000 abstract description 2
- 239000000969 carrier Substances 0.000 abstract description 2
- 230000037213 diet Effects 0.000 abstract description 2
- 230000000378 dietary effect Effects 0.000 abstract description 2
- 230000004048 modification Effects 0.000 abstract description 2
- 238000012986 modification Methods 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 238000000518 rheometry Methods 0.000 abstract 1
- 235000011962 puddings Nutrition 0.000 description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 12
- 238000003756 stirring Methods 0.000 description 11
- 229940044551 receptor antagonist Drugs 0.000 description 10
- 239000002464 receptor antagonist Substances 0.000 description 10
- 239000012530 fluid Substances 0.000 description 9
- 230000003474 anti-emetic effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 7
- 239000002111 antiemetic agent Substances 0.000 description 7
- 238000005538 encapsulation Methods 0.000 description 7
- 239000004302 potassium sorbate Substances 0.000 description 7
- 235000010241 potassium sorbate Nutrition 0.000 description 7
- 229940069338 potassium sorbate Drugs 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 229940125683 antiemetic agent Drugs 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
- 229920000053 polysorbate 80 Polymers 0.000 description 6
- 229940068968 polysorbate 80 Drugs 0.000 description 6
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 6
- 229920002245 Dextrose equivalent Polymers 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 239000002616 MRI contrast agent Substances 0.000 description 5
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 229960005019 pantoprazole Drugs 0.000 description 5
- 229940126409 proton pump inhibitor Drugs 0.000 description 5
- 239000000612 proton pump inhibitor Substances 0.000 description 5
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229960004503 metoclopramide Drugs 0.000 description 4
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 4
- YNWDKZIIWCEDEE-UHFFFAOYSA-N pantoprazole sodium Chemical compound [Na+].COC1=CC=NC(CS(=O)C=2[N-]C3=CC=C(OC(F)F)C=C3N=2)=C1OC YNWDKZIIWCEDEE-UHFFFAOYSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 4
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 235000016623 Fragaria vesca Nutrition 0.000 description 3
- 240000009088 Fragaria x ananassa Species 0.000 description 3
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 3
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 3
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 235000009499 Vanilla fragrans Nutrition 0.000 description 3
- 244000263375 Vanilla tahitensis Species 0.000 description 3
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 239000000832 lactitol Substances 0.000 description 3
- 235000010448 lactitol Nutrition 0.000 description 3
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 3
- 229960003451 lactitol Drugs 0.000 description 3
- 235000010449 maltitol Nutrition 0.000 description 3
- 239000000845 maltitol Substances 0.000 description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 3
- 229940035436 maltitol Drugs 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 229960004157 rabeprazole Drugs 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- YPELFRMCRYSPKZ-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 2
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920000569 Gum karaya Polymers 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 229940122236 Histamine receptor antagonist Drugs 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
- QQQIECGTIMUVDS-UHFFFAOYSA-N N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxybenzamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NCC1=CC=C(OCCN(C)C)C=C1 QQQIECGTIMUVDS-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 2
- 108010083204 Proton Pumps Proteins 0.000 description 2
- 241000934878 Sterculia Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 229910052788 barium Chemical class 0.000 description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical class [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000004330 calcium propionate Substances 0.000 description 2
- 235000010331 calcium propionate Nutrition 0.000 description 2
- 229930003827 cannabinoid Natural products 0.000 description 2
- 239000003557 cannabinoid Substances 0.000 description 2
- 229940065144 cannabinoids Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940109275 cyclamate Drugs 0.000 description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 2
- 238000007580 dry-mixing Methods 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 208000024798 heartburn Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- 229960005302 itopride Drugs 0.000 description 2
- 235000010494 karaya gum Nutrition 0.000 description 2
- 239000000231 karaya gum Substances 0.000 description 2
- 229940039371 karaya gum Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 2
- 229960004085 mosapride Drugs 0.000 description 2
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 229920000333 poly(propyleneimine) Polymers 0.000 description 2
- 229960003910 promethazine Drugs 0.000 description 2
- ZPMNHBXQOOVQJL-UHFFFAOYSA-N prucalopride Chemical compound C1CN(CCCOC)CCC1NC(=O)C1=CC(Cl)=C(N)C2=C1OCC2 ZPMNHBXQOOVQJL-UHFFFAOYSA-N 0.000 description 2
- 229960003863 prucalopride Drugs 0.000 description 2
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 2
- 229960000620 ranitidine Drugs 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000004317 sodium nitrate Substances 0.000 description 2
- 235000010344 sodium nitrate Nutrition 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical class [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- MFWNKCLOYSRHCJ-AGUYFDCRSA-N 1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]-3-indazolecarboxamide Chemical compound C1=CC=C2C(C(=O)NC3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-AGUYFDCRSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- NFLLKCVHYJRNRH-UHFFFAOYSA-N 8-chloro-1,3-dimethyl-7H-purine-2,6-dione 2-(diphenylmethyl)oxy-N,N-dimethylethanamine Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Cl)=N2.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 NFLLKCVHYJRNRH-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 244000287680 Garcinia dulcis Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 1
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 102100037346 Substance-P receptor Human genes 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 229940062327 aciphex Drugs 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940014175 aloxi Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940071731 antivert Drugs 0.000 description 1
- 229940059707 anzemet Drugs 0.000 description 1
- 229960001372 aprepitant Drugs 0.000 description 1
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940088007 benadryl Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 229940094219 bonine Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000015116 cappuccino Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229960003778 casopitant Drugs 0.000 description 1
- XGGTZCKQRWXCHW-WMTVXVAQSA-N casopitant Chemical compound C1([C@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)N2CCN(CC2)C(C)=O)=CC=C(F)C=C1C XGGTZCKQRWXCHW-WMTVXVAQSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- QTFFGPOXNNGTGZ-LIFGOUTFSA-N chembl2368924 Chemical compound O.CS(O)(=O)=O.C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 QTFFGPOXNNGTGZ-LIFGOUTFSA-N 0.000 description 1
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940008871 dexilant Drugs 0.000 description 1
- 229960004993 dimenhydrinate Drugs 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- KWORUUGOSLYAGD-YPPDDXJESA-N esomeprazole magnesium Chemical compound [Mg+2].C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C.C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C KWORUUGOSLYAGD-YPPDDXJESA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 210000001914 gastric parietal cell Anatomy 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000003630 glycyl group Chemical class [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical class C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 229940099262 marinol Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 229960002967 nabilone Drugs 0.000 description 1
- GECBBEABIDMGGL-RTBURBONSA-N nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 description 1
- 229940112641 nexium Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 229960002131 palonosetron Drugs 0.000 description 1
- ALAGDBVXZZADSN-UHFFFAOYSA-N pentazine Chemical compound C1=NN=NN=N1 ALAGDBVXZZADSN-UHFFFAOYSA-N 0.000 description 1
- 229940107333 phenergan Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229940032668 prevacid Drugs 0.000 description 1
- 229940089505 prilosec Drugs 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229940061276 protonix Drugs 0.000 description 1
- KRCQSTCYZUOBHN-UHFFFAOYSA-N rabeprazole sodium Chemical compound [Na+].COCCCOC1=CC=NC(CS(=O)C=2[N-]C3=CC=CC=C3N=2)=C1C KRCQSTCYZUOBHN-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229940023942 remeron Drugs 0.000 description 1
- LECZXZOBEZITCL-UHFFFAOYSA-N revaprazan Chemical compound C1CC2=CC=CC=C2C(C)N1C(C(=C(C)N=1)C)=NC=1NC1=CC=C(F)C=C1 LECZXZOBEZITCL-UHFFFAOYSA-N 0.000 description 1
- 229950000859 revaprazan Drugs 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940059160 sancuso Drugs 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0404—X-ray contrast preparations containing barium sulfate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/37—Sugar alcohols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0495—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound intended for oral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- compositions for dysphagia assessment are provided.
- Dysphagia or abnormal swallowing of foods and/ or liquids, affects people all ages from the newborn to the elderly. Management of dysphagia is commonly done by the prescription of texture-controlled diets. Ideally, tiie most appropriate modification of food consistencies should follow from a clear assessment o the swallowing problem. Rhcology and swallowing are connected at the diagnosis level.
- the "gold standard” technique is a videoffuoioscopic swallowing study (VFSS). The swallowing process can be visualized using vidcoradiography by employing either ready-to-use commercial contrast medium or by mixing food with barium sulphate (BaSO ⁇ , making it radiopaque. Unfortunately, there is no standardization to perform VFSS.
- the invention is directed to a composition suitable for dysphagia assessment by image diagnosis comprising an oral contrast agent, a carminative, a piokinetic agent, an antacid, and a hydrocolloid.
- the carminative is simethicone.
- Hie pi okinetic agent can be domperidone, benzamide, cisapride, erythromycin, itopi ide, mosapn ' de, metoclopramide, prucalopiide, renzapride, tegaserod, and mitemcinal.
- the antacid can be pantopraz le, omeprazole, lansoprazole, dexlansoprazole, esomeprazole, rabeprazole, cimetidine, and burimamide.
- the oral contrast agent can be selected from the group of radio opaque and contrast agents suitable for magnetic resonance imaging.
- the oral contrast agent can be a radio-opaque agent selected from the group consisting of barium sulphate and iodine.
- the oral contrast agent can be a contrast agent suitable for magnetic resonance imaging and can be selected from the group consisting of superparamagnetic iron oxide (SPIO), gadolinium chelates, manganese chelates, iron salts, barium sulphate, clay, perflubron, and natural products with high manganese concentration.
- the oral contrast agent can have a pharmaceutical acceptable coating.
- the hydrocolloid can be selected from the group of starch, cellulose, methylated cellulose, pectin, gum acacia, galactomannan, carubin, agar, carrageen, alginate, gelatin caseinate, xanthan, dextran, scleroglucan, guar, tara or combinations thereof.
- the composition can further comprise a polyalcohol wherein die polyalcohol is selected from the group of glycerol, glycol, erythritol, threitol, arabitol, xylitol, ribiiol, mannitol, sorbitol, dulcitol, fucitol, iditol, isomalt, maltitol, lactitol, and polyglycitol or combinations thereof.
- the composition c n comprise one or more compounds selected from the group consisting o flavoring agents, dextrines, stabilisers, non-saccharide sweeteners, and preservatives or combinations thereof.
- the invention also relates t o a composition suitable for the preparation of a composition for dysphagia assessment by image diagnosis comprising a guar gum in an amount of 0-0.5%, xanthan gum in an amount of 0.1%-1.5%, tara gum in an amount of 0.0-0.1%, carboxy- methyl cellulose in an amount of 0.0-1.0%, maltodextrin in an amount of 0.5-1.0%, optionally containing n oral contrast agent, a carminative, a piokinetic agent, an antacid, a flavoring agents, dextrine, stabilisers, non-saccharide sweeteners, and/or preservatives.
- a powdered preparation comprising any of the above described compositions can be prepared.
- a liquid preparation comprising the composition of any of the above claims can be prepared.
- the invention also relates to a method for producing the compositions o the invention as a powder comprising providing any of the above described compounds and mixing said compounds, (hereby producing the composition of the invention.
- An embodiment relates to a method for producing the liquid preparation of the invention comprising the steps for making a powder above further comprising adding water to the compounds, thereby dispersing the compounds in said water wherein the water is either provided before the compounds are added or the water is added after the entire powdery compositio has been prepared.
- 'Hie method can be performed at room temperature. The method can comprise the sterilization of the obtained mixt tire or dispersion.
- a method for imaging the swallowing of a liquid by a subject by an x- ray or MRI imaging system comprising recording the x-ray or MR I signals emitted from a subject swallowing the liquid preparation of the invention and imaging the x-ra or MRI signals.
- the liquid preparation can comprise SPIO and an MRI imaging system is used in the practice the imaging method.
- Fig. 1 Liquid compositions of the. invention compared to commercial nectar-like contrast fluid.
- Fig, 2 Liquid compositions of the invention compared to commercial nectat-like contrast fluid.
- Fig. 3 Liquid compositions of die invention compared to commercial pudding-like contrast fluid.
- Fig. 4 Liquid compositions of the invention compared to commercial pudding- like contrast fluid.
- a carminative is a preparation that either prevents formation of gas in the gastrointestinal tract or facilitates the expulsion of said gas, thereby combating flatulence.
- Carminatives have been shown to decrease lower esophageal pressure, which on the other hand increases the risk of Gastroesophageal Reflux Disease (GERD) or 'heartburn. 1
- An example of a carminative is simethicone.
- An antiemetic is a drug that is effective against vomiting and nausea.
- Antiemetics are typically used to treat motion sickness and the side effects of opioid analgesics, general ana es lietics, and chemotherapy directed against cancer.
- Antiemetics in the sense of the invention can comprise prokinetic agents.
- a gaslroprokinetic agent, gastrokinctic, or prokinetic agent are all different names for the same type of drug. It is a type of drug which enhances gastrointestinal motility by increasing the frequency of contractions in the small intestine or making them stronger, but without disrupting their rhythm. They are used to relieve gastrointestinal symptoms such as abdominal discomfort, bloating, constipation, heart burn, nausea, and vomiting (insofar the)' can overlap with antiemetic agents).
- Prokinetic drugs can be M 3 ⁇ 4 receptor antagonists (tliereby inhibiting acetylcholine release) and 5-HT, antagonists.
- Prokinetic drugs can be beiv/amide, cisapride, domperidone, erythromycin, itopride, mosapride, metoclopramide, prucalopride, renzapride, tegaserod, or mitemcinal. Prokinetic agents can have antiemetic effects.
- Antiemetics include, but are not limited to, 5-HT 3 receptor antagonists (these block serotonin receptors in the central nervous system and gastrointestinal tract), dopamine antagonists, N 1 receptor antaganists, antihistamines (11, histamine receptor antagonists), cannabinoids, benzodiazepines, anticholinergics, steroids (e.g. dexmethasone).
- 5-HT 3 receptor antagonists can be. (respective trademarks are provided in brackets) dolasetron (Anzemet), granisetron (Kytiil, Sancuso), ondansetron (Zofran), tropisctron (Navoban), palonosetron (Aloxi), mirtazapine (Remeron), an antidepressant that also has antiemetic effects.
- Dopamine antagonists can be (respective trademarks are provided in brackets) domperidone, olanzapine, dropcridol, haloperidol, chlorpromazine, promethazine, prochlorperazine, or metoclopramide (Rcglan).
- NK1 receptor antagonist can be aprepitant and casopitant.
- Antiliistamines can be (respective trademarks are provided in brackets) cyc!izine, diphenhydramine (Benadryl), dimenhydrinate (Gravol, Diamamine),meclozine (Bonine, Antivert), promethazine (Pentazine, Phenergan, Promaeot), hydroxyzine.
- Cannabinoids can be cannabis, dronabinol (Marinol), or nabilone (Cesairiet).
- Benzodiazepines can be midazolam or lorazepam.
- Anticholinergics can be hyoscine (also known as scopolamine).
- An example of a steroid is dexaniethasone.
- Antacids ate agents that reduce acidity in the gastiOintestinac tract. Basically two classes of agents are available: agents that neutralize the produced acid (curing of symptoms) or agents that prevent the production of acid at the source (H 2 -receptor antagonists, proton pump inhibitors). Antacids in the sense of the invention are H ? -receptor antagonists and proton pump inhibitors. Thus, the invention is directed to antacids that prevent the production of acid.
- Proton-pump inhibitors are a group of drugs whose main action is a pronounced and long-lasting reduction of gastric acid production.
- Proton pump inhibitors act by irreversibly blocking the hydrogen / otassium adenosine triphosphatase enzyme system (the H+/ + ATPase, or more commonly gastric proton pump) of the gastric parietal cells.
- the proton pump is the terminal stage in gastric acid secretion, being directly responsible for secreting H+ ions into the gastric lumen, making it an ideal target for inhibiting acid secretion.
- PPIs are omeprazole (brand names: Losec, Prilosec, Zegerid, ocid, Lomac, Omepral, Omcz), lansoprazole (brand names: Prevacid, Zoton, Monolitum, Inhibitol, Levant, Luptzo!e), dexlansoprazole (brand name: Kapidex, Dexilant), esomeprazole (brand names: Nexium, Esot ex), pantoprazole (brand names: Protonix, Somac, Pantoloc, Pantozo!, Zutcal, Zentro, Pan, Controloc), rabeprazole (brand names: Zcchin, Rabecid, N'/ole- 1), AcipHex, Pariet, Rabeloc, and Revaprazan).
- H 2 receptor antagonists e a class of drugs used to block the action histamine on parietal cells in the stomach, decreasing the production f acid by these, cells.
- I I 2 receptor antagonists arc citnetidine, burimamide, and ranitidine,
- a hydiocolloid is defined as colloidal system wherein the colloid particles are dispersed in water.
- a hydiocolloid has colloid particles spread throughout water, and depending on the quantity of water available can take different states, e.g., gel or sol (liquid).
- a hydiocolloid can be selected from the group of starch, cellulose, methylated cellulose, pectin, gum acacia, galactomannan, carubin, agar, carrageen, aliginate, gelatin caseinate, xanthan, dextran, scleroglucan, guar, tara, taracanth, karaya gum, locust bean gum or mixtures thereof.
- a dextrine is a hydroiysed form of starch wherein the hydroiysed forms have ⁇ glucose units connected in chains of variable length, in particular, in a range from three to nineteen glucose units and have a DE (dextrose equivalent) of between 3 lo 20. The glucose units are linked by a(l ⁇ 4) glycosidic bonds.
- a preferred dextrine is maltodextrin.
- Dextrose equivalent is a measure of the amount of reducing sugars present in a sugar product, relative to glucose, expressed as a percentage on a dry basis.
- the DE corresponds to the amount of glucose that, based on lOOg of the sugar product on a dry basis, has the same reducing power.
- a polyalcohol is a hydrogenated form of carbohydrate, whose carbonyl group (aldehyde or ketone, reducin sugar) has been reduced to a primary or secondary hydroxy! group.
- Sugar alcohols have (he general formula H(HCHO) Il+ 1 H.
- pharmaceutical acceptable polyalcohols are glycerol, crythritol, threitol, tabito!, xylitol, ribitol, mannitol, sorbitol, dulcitol, fucito!, iditol, isomalt, maltitol, lactitol, polyglycitol.
- Flavoring agents ate agents that contribute a flavor to a composition and exist in a wide variety of forms and flavours.
- citric acid can render a composition sour.
- Stabilisers are agents that enhance dispersion stability, by slowing down suspension phase separation.
- An example is polysorbate 80.
- Preservatives prevent decomposition a nutritional product or a product containing organic material by microbial growth or by undesirable chemical changes.
- examples are potassium sorbate, calcium propionate, sodium nitrate, sodium nitrite, and (sodium) benzoate.
- Non-saechafide sweeteners imitate or even multipl the effect of sugar in taste, usually with less food energy.
- Examples are aspartame, cyclamate, (sodium) saccharin, stevia, and sucralosc.
- a pre-encapsulated compound is compound that is prepared to be entrapped inside a fluid matrix or to have a solid coating.
- pre- encapsulation provides a firs encapsulation to the compound.
- the compound may be mixed with other pre-encapsulated or non-encapsulated compounds or remain unmixed.
- Th pre- encapsulated compound or the mixture of pre-encapsulated and other compounds may undergo a further encapsulation procedure.
- compositions can comprise a pharmaceutical active ingredient comprising compounds selected from the group consisting of a carminative and an antacid.
- the composition can comprise 0.05% to 0.3%, 0.10% to 0.20%, 0.125% to 0.175%, or 0. 15% of the pharmaceutical active ingredient.
- the amount of the carminative in the pharmaceutical ingredient can be 10-90% while the amount o the antacid can be 90-10%. Their combined amounts can make 100% of the pharmaceutical active ingredient.
- the skilled person based on the nature of the compound can determine any suitable amount for the composition.
- the pharmaceutical active ingredient can further comprise a prokinetic agent without altering the total amount of the pharmaceutical active ingredient in die composition.
- a prokinetic agent is comprised in the pharmaceutical active ingredient
- the combined amounts of the carminative and the antacid make up for (100% - the amount in % of the prokinetic agent comprised) of the pharmaceutical active ingredient.
- the amount f the carminative in the pharmaceutical ingredient can be 10 80% while the amount of the antacid can be 80-10% and the amount the prokinetic agent can be 80 10.
- Their combined amounts can make 100% of the pharmaceutical active ingredient.
- the skilled person based on the nature of the compound can determine any suitable amount f r the composition.
- the carminative can be simethicone.
- the antacid can be selected from the group of H 2 -receptor antagonists and proton pump inhibitors.
- the antacid can be selected from the group consisting o omeprazole, lansoprazole, dcxlansoprazole, esomeprazole, pantoprazole, rabeprazole, cimetidine, burimamidc, and ranitidine. Particularl preferred is pantoprazole.
- the prokinetic agent can be selected from the group consisting of ⁇ ⁇ receptor antagonists and 5-1 1T 4 antagonists.
- Preferred prokinetic drugs can be benzamide, cisapride, domperidonc, erythromycin, itopride, mosapride, metoclopramide, prucalopride, renzapride, tcgaserod, or mitemcina!. Particularly preferred is domperidone. Domperidone can also have antiemetic properties.
- the composition can comprise agents with antiemetic properties (antiemetic agents).
- Oral contrast agents are agents that can be visualized during dysphagia assessment by image diagnosis such as X-ray or magnetic resonance imaging (Mill). Suitable contrast agents are, depending on the used imaging technique, radio opaque (and therefore suitable for X-ray analysis) and/or can be made visible by magnetic resonance imaging (MRI contrast agents). Radio-opaque contrast agents are salts of iodine or barium. A preferred radio-opaque contrast agent is barium sulphate.
- MRI contrast agents are selected from the group consisting of gadolinium chelates, manganese chelates, iron salts, superparamagnetic iron oxide (SPIO), barium sulphate, clay, perflubron, and natural products with high manganese concentration (e.g. blueberry and green tea). Particularly preferred is SPIO.
- compositions can comprise 20 ⁇ 40%, 25-35%, or 30% of a radio-opaque contrast agent, in particular, barium sulphate.
- a radio-opaque contrast agent in particular, barium sulphate.
- the radio-opaque contrast agent is pre- encapsula ted.
- compositions can comprise 0.01-0.20, 0.04 -0.1 %, 0.05 0.10% of an MRI contrast agent, in particular, SPIO.
- the MRI contrast agent is pre-encapsulated.
- the contrast agents can be pre-encapsulated .
- the encapsulating agent c n be a gum or a dextrine, in particular, a maltodextrine.
- the barium sulphate is provided in a pre- encapsulated form.
- barium sulphate is pre-encapsulated with a gum.
- MRI contrast agents can be pre-encapsulated with dextrin.
- hydrocolloid or the combination of hydrocolloids can define the iheological properties of the composition.
- the hyd ocolloid can be selected from the group of starch, cellulose, methylated cellulose, carboxy-methylated cellulose (CMC), pectin, gum acacia, galactomannan, cambin, aga , carrageen, alginate, gelatin caseinate, xanthan, dextran, scle oglucan, guar, rata, taracanth, karaya gum, locust bean gum or mixtures thereof.
- the composition can comprise hydrocolloids in an amount of 0.75 -1.75%, 1.0-1.5%, 1.1 -1.4%, 1.2-1.35%, or 1.3%. Particularly preferred is guar gum.
- guar gum in a range from 0-1.5%, 0.14.5%, 0.2-1.4%, 0.3-1.3%, 0.4-1.2%, 0.5-1.1%, 0.6-1.0%, 0.7- 0.9%, 0.1-0.5%, 0.1-0.4%, 0.1- 0.3%, 0.2-0.35%, 0.3-0.75%, or 0.4-0.6%.
- An amount of 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.75, or 0,8% of gu r gum is also disclosed.
- xanthan gum is particularly preferred. Particularly preferred is xanthan gum in a range from 0-1,5%, 0.1-1.5% 0.2-1.4%, 0.3-1.3%, 0.4-1.2%, 0.5-1.1%, 0.6 1.0%, 0.7-0.9%, 0.7-1.3%, 0.8-1.2%, 0.9-1.1%, 0.05-0.4%, 0.1-0.3%, 0.1-0.2%. An amount of 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.75, 0.8%, 0.9%, or 1.0% of xanthan gum is also disclosed.
- methylated cellulose is particularly preferred. Particularly preferred is methylated cellulose in a range from 0-1.5%, 0.1-1.5% 0.2-1.4%, 0.3-1.3%, 0.4-1.2%, 0.5- 1.1%, 0.6 1.0%, or 0.7-0.9%. An amount of 0.0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0,75, 0.8% of methylated cellulose is also disclosed.
- the preferred methylated cellulose is carboxymcthylat cellulose (CMC).
- the composition can also comprise t a gum.
- the composition can compris tara gum in an amount of 0.0, 0.0 -0.2%, 0.05-0.15%, or 0.1 %.
- every range defined for one radi ocolloid can be combined with every range defined for a second or more hydrocolloids.
- the composition can comprise dextrines.
- the composition can comprise dextrines in an amount of 0.25-1.5%, 0.5-1.25%, 0.75- 1.0%, 0.5, 0.8, or 1.0%.
- the preferred dextrine is maltodex trin.
- Stabilizers can be present in an amount of 0.3-0.5% or 0.4 %.
- the stabilizer can be selected from the group consisting of polysorbate 80, ceteaiyl alcohol, polysorbate 20, and cetcareth 20.
- the preferred stabiliser is polysorbate 80.
- Flavouring agents can be present in an amount of 0.1-5.0%, 0.1-1.0%, 0.2-0.5%, 0.25-0.35%, or 0.3%.
- Preferred flavouring agents are cit ic acid, glutamic acid salts, glycine salts, guanylic acid salts, inosinic acid salts, 5'-ribonucleotide salts, acetic acid, ascorbic acid, fumaric acid, lactic acid, malic acid, phosphoric acid, and tartaric acid, or combinations thereof.
- the preferred flavouring agent is citric acid providing a sour taste.
- Suitable flavouring agents ate also those that have the taste of vanilla, strawberry, chocolate, cappuccino, mango, orange, peach, etc., wherein each of them can belong to the group of synthetic, natural- or natural identical flavours.
- compositions can comprise pharmaceutical acceptable polyalcohols.
- the polyalcohols can be present in an amount of 0.5-4.0%, 1 -3.5%, 1.5-3.0%, 1.25-2.5% or 2.0%.
- Polyalcohols have the general formula H(HCHO) n+1 H.
- Pharmaceutical acceptable polyalcohols can be selected from the group consisting of glycerol (glycerin), erythrifol, threitol, arabitol, xylitol, ribitol, mannitol, sorbitol, dulcitol, fucitol, iditol, isomalt, maltitol, lactitol, polyglycitol.
- Polyalcohols comprisin 3 or 4 carbon atoms, in particular, comprising 3 carbon atoms are preferred. Particularly preferred is glycerol.
- Preservatives can be present in an amount of 0.0-0.4%, 0.1 - 0.3%, or 0,2%.
- the preservative can be selected from the group consisting of potassium sorbate, calcium propionate, sodium nitrate, sodium nitrite, and (sodium) benzoatc, or mixtures thereof.
- Preferred preservatives are potassium sorbate and sodium benzoatc.
- potassium sorbate is present in an amount of 0.1 % and sodium benzoate in an amount of 0.1%
- Non-saccha ide sweeteners can be present in an amount of 0.1-0.3% or 0.2%.
- the sweeteners ate selected from the group consisting of aspartame, cyclamate, (sodium) saccharin, stcvia, and sucralose.
- the composition contains sodium saccharin.
- a further preferred embodiment relates to formulations having nectar- or pudding like characteristics. These formulations are already disclosed by die combination,? of compounds and ranges described above and are here merely presented for further clarification of the invention.
- compositions comprising hydrocoUoids that show the same viscosity behavior like nectar and pudding formulations of die prior art (e.g., Varibar Nectar barium Sulfate Suspension and Varibar Pudding Barium Sulfate Esophageal Paste).
- the claimed formulations show a steady state shear viscosity ( ⁇ in IVs) in a shear range of
- a pudding formulation can comprise 0.0-0.5% or 0.4-0.6% guar gum, 0.8 -1.2% or 1.0% xanthan gum, and 25-35% or 30% barium sulphate, 0.4-0.6% or 0.5% maltodextrin,.
- a further pudding formulation can comprise 0.0-1.0% guar guam, 1.0-1.5% or 1.25% xanthan gum, 0.5-1.0% CMC, 0.4-0.6% or 0.5% maltodextrin, and 0.05- 0.10% pre-encapsulated
- Both pudding formulations can comprise 0.3% citric acid, 2.0% glycerol, 0.4% polysorbate 80, 0.1% potassium sorbate, 0.2% sodium saccharin, 0,1% sodium benzoate, 0.3% sodium citrate, and 0.15% of a pharmaceutical active ingredient comprising a carminative, a prokinetic agent, and an antacid (e.g. simethicone, domperidone, pantobrazole).
- a pharmaceutical active ingredient comprising a carminative, a prokinetic agent, and an antacid (e.g. simethicone, domperidone, pantobrazole).
- nectar formulation can comprise 0.0-0.3% or 0.1-0.2 guar guam, 0.1 0.4% or 0.25% xanthan gum, 0.0-0.1 lata gum and 25-35% or30% barium sulphate, 0.9-1.1%. or 1.0% maltodextrin,.
- a further nectar formulation can comprise 0.1 -0.5% guar guam, 0.1-0.5% or 0.30% xanthan gum, 0.1 0.5 tara gum, 0.9-1.1 % or 1.0% maltodextrin, and 0.05 0.10% pre- encapsulated SPIO.
- Both nectar formulations can comprise 0.3% citric acid, 2.0% glycerol, 0.4% polysorbate 80, 0.1% potassium sorbate, 0.04% sodium saccharin, 0.1% sodium benzoate, 0.3% sodium citrate, nd 0.15% of pharmaceutical active ingredient comprising a carminative, a prokinetic agent, and n antacid (e.g. simethicone, domperidone, pantobrazole).
- a carminative e.g. simethicone, domperidone, pantobrazole
- a method for producing liquid compositions of the inventions comprises the steps of providing any f the compounds or a subgroup of the compounds described above, mixing said compounds and thereby producing the composition of the invention.
- the compounds can be the carminative, the antacid, the oral contrast agent, and the hydrocolloid.
- the oral contrast agent may be provided in a pre-encapsulated form.
- a further compound may be a prokinetic agent .
- a further compound may be a polyalcohol.
- the water is provided and the compounds are added to the water.
- water can be added to the prepared mixture or solution.
- the obtained solution may be a true solution wherein all compounds are dissolved or alternatively a suspension or dispersion.
- the oral contrast agent is pie encapsulated with a compound (gum, maltodextiin or others) in a watery dispersion (made from purified water) by mixing the encapsulating agent and the oral contrast agent under stirring.
- a compound gum, maltodextiin or others
- a watery dispersion made from purified water
- barium sulfate is pie-encapsulated with a gum and SPIO is pre-encapsu!ated with a dextrin (e.g. maltodextiin).
- the stilling speed can be 100 to 500 rpm, 200 to 400 rpm, or 300 tpm.
- the stirring/incubation time can be 1 to 6 Min, 2 to 4 Min, and preferentially 3 Min yielding a first dispersion.
- the remaining compounds can be mixed separately by combining water, hydrocolloids (e.g. gums), and other compounds.
- the mixing occurs under stirring.
- the stirring speed can be 100 to 500 rpm, 200 to 400 rpm, or 300 rpm.
- the stirring/incubation time can be 1 to 20 Min, 5 to 15 Min, and preferentially 10 Min yielding a second dispersion.
- First and second dispersions can be mixed under stirring.
- the stirring speed can be 500 to 2000 rpm, 750 to 1500 rpm, or 1000 rpm.
- the stirring/incubation time can be 1 to 60 Min, 15 to 45 Min, and preferentially 30 Min yielding a third dispersion.
- Room temperature can be any value between 20°C-25°C, or 20°C, or 21 °C, or 22° C, or 23°C, 24°C, or 25°C.
- the obtained solution or mixture can be sterilized.
- the sterilization can be any suitable form of sterilization method suitable for a liquid dispersion like thermal sterilization or sterilization by irradiation.
- the liquid dispersion is thermally sterilized. Conditions for thermally sterilizing a composition are provided in this description.
- a method for producing a powdered composition of tills invention comprises the steps of providing any of the compounds or a subgroup of the compounds described above, dry mixing said compounds, then encapsulating the compounds.
- the compounds of the composition that is prepared by mixing can be one or more hydrocolloids and an oral contrast agent.
- the composition ca also comprise a compound selected from the group consisting of a carminative, a prokinetic agent an antacid, r mixtures thereof.
- the composition ca also comprise flavours or polya!cholhols (e.g. glycerol).
- the mixing can be achieved with the use of a fluidizecl bed and thereby producing the powdered composition of the invention.
- the compounds can be a carminative, an antacid, a prokinetic agent, an oral contrast agent, and/ or a hydrocolloid.
- the oral contrast agent may be provided in a pre- encapsulated fomi.
- Th oral contrast agent can be pre-encapsulated with a compound (g m, maltodextrin or others) in a watery dispersion (made from purified water) by mixing the pre- encapsulating agent and the oral contrast agent under stirring.
- barium sul ate is pre-encapsulated with a gum and SPIO is pre-encapsulated with a dextrin (e.g. maltodextrin).
- the stirring speed can be 100 to 500 rpm, 200 to 400 rpm, or 300 rpm.
- the stirring/incubation time can be 1 to 6 Min, 2 to 4 Min, and preferentially 3 Min yielding a dispersion. Then the obtained dispersion is dried to yield a powdered form of the pre-encapsulated contrast agent and is ready for use in the above described dry mixing method.
- the powder composition obtainable by the above method contains all non-liquid compounds that are required for preparing a composition for dysphagia assessment. Only water needs to be added to reconstitute a dispersion.
- a method for imaging the swallowing of a liquid by a subject by an x-ray or MRI imaging system comprises recording the x-ra or Mill signals emitted from a subject swallowing a liquid preparation of the compositions provided in this description and imaging the x-ray or MRI signals.
- the subject can be exposed to x-rays when the x-ray images ate recorded.
- Methods for recording x-ray or MRI signals are known in the art.
- the liquid compositions disclosed in this description are different from the liquid compositions of the prior art.
- Hie method comprises the imagin steps defined above followed by a diagnostic phase where it is analysed whether the subject exhibits signs of dysphagia.
- the analysis can be performed by visual inspection by a skilled practitioner or by an automated method, for example, assisted by a computer program.
- the i f value o the solution can be between 3 and 6, between 4 and 5, between 4.3 and 4.6, or can be 4.4 or 4.5.
- compositions of the invention can be thermally sterilized (at a temperature that is above room temperature, i.e. above 25 C).
- the sterilization is performed above 100°C, more preferably 105 und 150°C, in particular, between 110 und 130°C, or at 121°C.
- the length of the period at elevated temperature can be from 2 seconds up to 30 min., up to 25 min., in particular, between 10 min. and 20 min., or be 15 min.
- the sterilization can be performed at regular atmospheric pressure (1.0 bar) or at elevated pressure (1.8 to 2.0 bar).
- the liquid compositions can be provided as ready-to-use compositions in containers of 150 ml, 200 ml, 250 ml, or 300 ml size or as powders to be reconstituted by adding the necessary amount of water to produce, for instance, nectar-like or pudding like compositions compositions in containers of 50 ml, 200 ml, 250 ml, or 300 ml size.
- the patient is positioned laterally before a suitable x-ray or Mill device and asked to swallow one of the compositions.
- a suitable recording equipment is then used to visualize and record the passage of the composition through the mouth and throat down to the esophagus during swallowing.
- the invention has several advantages over the swallow test feeds f the prior art.
- the unique combination o hydro colloids allows to better simulate the theological behavior of nectar and pudding like compositions.
- compositions contain in some embodiments a carminative, a prokinetic agent, and an antacid (for example, simethicone, domperidone, and pantoprazole), a combination that has not been used before fo dysphagia assessment.
- a carminative for example, simethicone, domperidone, and pantoprazole
- an antacid for example, simethicone, domperidone, and pantoprazole
- This mixture has been used aiming to avoid/prevent the negative effects of oral contrast media, in particular, barium sulphate on the patient. Barium sulphate causes nausea, vomiting, diarrhea, constipation, abdominal pain, etc.
- These active ingredients do not modify the performance of these contrast media but do improve patient's quality of life after dysphagia diagnosis tests.
- the chosen combination has been found to be particularly beneficial for the patients' well-being fter swallowing a composition containing an oral contrast agent.
- flavouring of the formulations allows a better compliance.
- the formulations provided by the invention are more likely to be accepted by the patient.
- glycerol can enhance the suspension stability and favours hydrocolloid dispersion, thereby avoiding the formation of aggregates and preventing phase separation.
- the radio opaque, contrast agent e.g. barium sulphate
- the barium sulphate pre-cncapsulation contributes to a decrease, in barium sulphate adhesion to the stomach and intestinal walls.
- the pre-encapsulation improves suspension stability, improves organoleptic properties, improves particle size distribution, decreases barium sulphate adhesion to the stomach and intestinal walls.
- the pie-encapsulation of SPIO improves iron particle stability, avoids agglomeration, and favors diagnosis by MRI.
- a powder can be prepared from a composition having the radio opaque contrast agent in p e-encapsulated form which allows easier handling, storage and shelf life of the composition.
- the powder may comprise any of the powdery compounds described in the detailed description.
- this liquid formulation can be submitted to thermal sterilization in a final preparative step- Finally, this is the first time SPIO is used for dysphagia assessment.
- contrast media for dysphagia assessment available containing superparamagnetic iron oxide in the market.
- Barium sulphate is the "standard" contrast agent for dysphagia assessment.
- barium sulphate cannot be metabolised by the human body.
- iron diffuses to the blood stream, being its excess metabolised and eliminated by macrophages, spleen, liver and faeces.
- Mill contrast agents has advantages.
- Example 1 Exemplary compositions comprising supetpaiamagnetic iron oxide
- Example 2 Exemplary compositions comprising barium sulphate The formulations were produced according to following scheme:
- Dispersions A and B were prepared separately and then mixed. The obtained mixture was treated with an agitator (IKA T50 basic) as indicated above yielding a dispersion C. Finally the dispersion was subjected to sterilization.
- IKA T50 basic an agitator
- compositions A-C were prepared.
- compositions I IV were prepared.
- the viscosities of these fluids were measured in relation to the shear rate ( in s "1 ) as above at 25°C.
- the control pudding was V atibat Pudding Barium Sulfate Esophageal Paste (Ezem, Canada). As can be observed in Fig. 3, only composition A matches die flow behavior of the control pudding.
- the viscosities of these fluids were measured in relation to the sheaf rate ( ⁇ in s "1 ) as above at 25°C.
- the control pudding was Vaiibar Pudding Barium Sulfate Esophageal Paste (Ezem, Canada). As can be observed Fig. 4, only the composition II does not match the flow behavior of the control pudding.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Radiology & Medical Imaging (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
Abstract
Dysphagia, or abnormal swallowing of foods and/ or liquids, affects people of all ages from the newborn to the elderly. Management of dysphagia is commonly done by the prescription of texture-controlled diets. Ideally, the most appropriate modification of food consistencies should follow from a clear assessment of the swallowing problem. Rheology and swallowing are connected at the diagnosis level. The "gold standard" technique is a videofluoroscopic swallowing study (VFSS). The swallowing process can be visualized using videoradiography by employing either ready-to-use commercial contrast medium or by mixing food with barium sulphate (BaSO4), making it radiopaque. Unfortunately, there is no standardization to perform VFSS. This lack of standardization leads to variability of results as well as their interpretation. In practice, lack of standardization often requires that individual speech pathologist, dieticians and dysphagia food manufacturers determine their own dietary consistencies. Another possibility is the use of encapsulated MRI superparamagnetic contrast agents for oral administration. The main goal of this invention has been to develop new and improved formulations of carriers/vehicles for radio-opaque (barium sulphate) or magnetic contrast agents (superparamagnetic iron oxide) that can be used as ready-to-use/ powder commercial formulations as contrast media for imaging diagnosis (VFSS or MRI) of dysphagia.
Description
Compositions for dysphagia assessment
Background
Dysphagia, or abnormal swallowing of foods and/ or liquids, affects people all ages from the newborn to the elderly. Management of dysphagia is commonly done by the prescription of texture-controlled diets. Ideally, tiie most appropriate modification of food consistencies should follow from a clear assessment o the swallowing problem. Rhcology and swallowing are connected at the diagnosis level. The "gold standard" technique is a videoffuoioscopic swallowing study (VFSS). The swallowing process can be visualized using vidcoradiography by employing either ready-to-use commercial contrast medium or by mixing food with barium sulphate (BaSO^, making it radiopaque. Unfortunately, there is no standardization to perform VFSS. This lack of standardization leads to variabilit of results as well as their interpretation. In practice, lack of standardization often requires that individual speech pathologist, dieticians and dysphagia food manufacturers determine their own dietary consistencies. Another possibility is the use of encapsulated MRI superparamagnetic contrast agents for oral administration. The main goal of this invention has been to develop new and improved formulations f carriers/vehicles for radio-opaque (barium sulphate) or magnetic contrast agents (superparamagnetic iron oxide) that can be used as ready-to-use/ powder commercial formulations as contrast media for imaging diagnosis (VFSS or R!) f dysphagia.
Summary.
The invention is directed to a composition suitable for dysphagia assessment by image diagnosis comprising an oral contrast agent, a carminative, a piokinetic agent, an antacid, and a hydrocolloid. The carminative is simethicone. Hie pi okinetic agent can be domperidone, benzamide, cisapride, erythromycin, itopi ide, mosapn'de, metoclopramide, prucalopiide, renzapride, tegaserod, and mitemcinal. The antacid can be pantopraz le, omeprazole, lansoprazole, dexlansoprazole, esomeprazole, rabeprazole, cimetidine, and burimamide. The oral contrast agent can be selected from the group of radio opaque and contrast agents suitable for magnetic resonance imaging. The oral contrast agent can be a radio-opaque agent selected from the group consisting of barium sulphate and iodine. The oral contrast agent can be a contrast agent suitable for magnetic resonance imaging and can be selected from the group consisting of superparamagnetic iron oxide (SPIO), gadolinium chelates, manganese chelates, iron salts, barium sulphate, clay, perflubron, and natural products with high manganese concentration. The oral contrast agent can have a pharmaceutical acceptable coating. The hydrocolloid can be selected from the group of starch, cellulose, methylated cellulose, pectin, gum acacia, galactomannan, carubin, agar, carrageen, alginate, gelatin caseinate, xanthan, dextran, scleroglucan, guar, tara or combinations thereof. The composition can further comprise a polyalcohol wherein die polyalcohol is selected from the group of glycerol, glycol, erythritol, threitol, arabitol, xylitol, ribiiol, mannitol, sorbitol, dulcitol, fucitol, iditol, isomalt, maltitol, lactitol, and polyglycitol or combinations thereof. The composition c n comprise one or more compounds selected from the group consisting o flavoring agents, dextrines, stabilisers, non-saccharide sweeteners, and preservatives or combinations thereof.
The invention also relates t o a composition suitable for the preparation of a composition for dysphagia assessment by image diagnosis comprising a guar gum in an amount of 0-0.5%, xanthan gum in an amount of 0.1%-1.5%, tara gum in an amount of 0.0-0.1%, carboxy- methyl cellulose in an amount of 0.0-1.0%, maltodextrin in an amount of 0.5-1.0%, optionally containing n oral contrast agent, a carminative, a piokinetic agent, an antacid, a flavoring agents, dextrine, stabilisers, non-saccharide sweeteners, and/or preservatives.
A powdered preparation comprising any of the above described compositions can be prepared. Alternatively, a liquid preparation comprising the composition of any of the above claims can be prepared.
The invention also relates to a method for producing the compositions o the invention as a powder comprising providing any of the above described compounds and mixing said compounds, (hereby producing the composition of the invention.
An embodiment relates to a method for producing the liquid preparation of the invention comprising the steps for making a powder above further comprising adding water to the compounds, thereby dispersing the compounds in said water wherein the water is either provided before the compounds are added or the water is added after the entire powdery compositio has been prepared. 'Hie method can be performed at room temperature. The method can comprise the sterilization of the obtained mixt tire or dispersion.
Particularly preferred is a method for imaging the swallowing of a liquid by a subject by an x- ray or MRI imaging system comprising recording the x-ray or MR I signals emitted from a subject swallowing the liquid preparation of the invention and imaging the x-ra or MRI signals. In a preferred embodiment, the liquid preparation can comprise SPIO and an MRI imaging system is used in the practice the imaging method.
Brief description of the figutes
Fig. 1 Liquid compositions of the. invention compared to commercial nectar-like contrast fluid.
Fig, 2 Liquid compositions of the invention compared to commercial nectat-like contrast fluid.
Fig. 3 Liquid compositions of die invention compared to commercial pudding-like contrast fluid.
Fig. 4 Liquid compositions of the invention compared to commercial pudding- like contrast fluid.
Qefitiitions
A carminative is a preparation that either prevents formation of gas in the gastrointestinal tract or facilitates the expulsion of said gas, thereby combating flatulence. Carminatives have been shown to decrease lower esophageal pressure, which on the other hand increases the risk of Gastroesophageal Reflux Disease (GERD) or 'heartburn.1 An example of a carminative is simethicone.
An antiemetic is a drug that is effective against vomiting and nausea. Antiemetics are typically used to treat motion sickness and the side effects of opioid analgesics, general ana es lietics, and chemotherapy directed against cancer. Antiemetics in the sense of the invention can comprise prokinetic agents.
A gaslroprokinetic agent, gastrokinctic, or prokinetic agent are all different names for the same type of drug. It is a type of drug which enhances gastrointestinal motility by increasing the frequency of contractions in the small intestine or making them stronger, but without disrupting their rhythm. They are used to relieve gastrointestinal symptoms such as abdominal discomfort, bloating, constipation, heart burn, nausea, and vomiting (insofar the)' can overlap with antiemetic agents). Prokinetic drugs can be M¾ receptor antagonists (tliereby inhibiting acetylcholine release) and 5-HT, antagonists. Prokinetic drugs can be beiv/amide, cisapride, domperidone, erythromycin, itopride, mosapride, metoclopramide, prucalopride, renzapride, tegaserod, or mitemcinal. Prokinetic agents can have antiemetic effects.
Antiemetics include, but are not limited to, 5-HT3 receptor antagonists (these block serotonin receptors in the central nervous system and gastrointestinal tract), dopamine antagonists, N 1 receptor antaganists, antihistamines (11, histamine receptor antagonists), cannabinoids, benzodiazepines, anticholinergics, steroids (e.g. dexmethasone).
5-HT3 receptor antagonists can be. (respective trademarks are provided in brackets) dolasetron (Anzemet), granisetron (Kytiil, Sancuso), ondansetron (Zofran), tropisctron (Navoban), palonosetron (Aloxi), mirtazapine (Remeron), an antidepressant that also has antiemetic effects.
Dopamine antagonists can be (respective trademarks are provided in brackets) domperidone, olanzapine, dropcridol, haloperidol, chlorpromazine, promethazine, prochlorperazine, or metoclopramide (Rcglan).
NK1 receptor antagonist can be aprepitant and casopitant.
Antiliistamines (I i, histamine receptor antagonists) can be (respective trademarks are provided in brackets) cyc!izine, diphenhydramine (Benadryl), dimenhydrinate (Gravol,
Diamamine),meclozine (Bonine, Antivert), promethazine (Pentazine, Phenergan, Promaeot), hydroxyzine.
Cannabinoids can be cannabis, dronabinol (Marinol), or nabilone (Cesairiet).
Benzodiazepines can be midazolam or lorazepam.
Anticholinergics can be hyoscine (also known as scopolamine).
An example of a steroid is dexaniethasone.
Antacids ate agents that reduce acidity in the gastiOintestinac tract. Basically two classes of agents are available: agents that neutralize the produced acid (curing of symptoms) or agents that prevent the production of acid at the source (H2-receptor antagonists, proton pump inhibitors). Antacids in the sense of the invention are H?-receptor antagonists and proton pump inhibitors. Thus, the invention is directed to antacids that prevent the production of acid.
Proton-pump inhibitors (PPIs) are a group of drugs whose main action is a pronounced and long-lasting reduction of gastric acid production. Proton pump inhibitors act by irreversibly blocking the hydrogen / otassium adenosine triphosphatase enzyme system (the H+/ + ATPase, or more commonly gastric proton pump) of the gastric parietal cells. The proton pump is the terminal stage in gastric acid secretion, being directly responsible for secreting H+ ions into the gastric lumen, making it an ideal target for inhibiting acid secretion. PPIs are omeprazole (brand names: Losec, Prilosec, Zegerid, ocid, Lomac, Omepral, Omcz), lansoprazole (brand names: Prevacid, Zoton, Monolitum, Inhibitol, Levant, Luptzo!e), dexlansoprazole (brand name: Kapidex, Dexilant), esomeprazole (brand names: Nexium, Esot ex), pantoprazole (brand names: Protonix, Somac, Pantoloc, Pantozo!, Zutcal, Zentro, Pan, Controloc), rabeprazole (brand names: Zcchin, Rabecid, N'/ole- 1), AcipHex, Pariet, Rabeloc, and Revaprazan).
The H2 receptor antagonists e a class of drugs used to block the action histamine on parietal cells in the stomach, decreasing the production f acid by these, cells. I I2 receptor antagonists arc citnetidine, burimamide, and ranitidine,
A hydiocolloid is defined as colloidal system wherein the colloid particles are dispersed in water. A hydiocolloid has colloid particles spread throughout water, and depending on the quantity of water available can take different states, e.g., gel or sol (liquid). A hydiocolloid can be selected from the group of starch, cellulose, methylated cellulose, pectin, gum acacia, galactomannan, carubin, agar, carrageen, aliginate, gelatin caseinate, xanthan, dextran, scleroglucan, guar, tara, taracanth, karaya gum, locust bean gum or mixtures thereof.
A dextrine is a hydroiysed form of starch wherein the hydroiysed forms have Ό glucose units connected in chains of variable length, in particular, in a range from three to nineteen glucose units and have a DE (dextrose equivalent) of between 3 lo 20. The glucose units are linked by a(l→4) glycosidic bonds. A preferred dextrine is maltodextrin.
Dextrose equivalent (DE) is a measure of the amount of reducing sugars present in a sugar product, relative to glucose, expressed as a percentage on a dry basis. The DE corresponds to the amount of glucose that, based on lOOg of the sugar product on a dry basis, has the same reducing power.
A polyalcohol is a hydrogenated form of carbohydrate, whose carbonyl group (aldehyde or ketone, reducin sugar) has been reduced to a primary or secondary hydroxy! group. Sugar alcohols have (he general formula H(HCHO)Il+ 1H. Examples of pharmaceutical acceptable polyalcohols are glycerol, crythritol, threitol, tabito!, xylitol, ribitol, mannitol, sorbitol, dulcitol, fucito!, iditol, isomalt, maltitol, lactitol, polyglycitol.
Flavoring agents ate agents that contribute a flavor to a composition and exist in a wide variety of forms and flavours. For example, citric acid can render a composition sour.
Stabilisers are agents that enhance dispersion stability, by slowing down suspension phase separation. An example is polysorbate 80.
Preservatives prevent decomposition a nutritional product or a product containing organic material by microbial growth or by undesirable chemical changes. Examples are potassium sorbate, calcium propionate, sodium nitrate, sodium nitrite, and (sodium) benzoate.
Non-saechafide sweeteners imitate or even multipl the effect of sugar in taste, usually with less food energy. Examples are aspartame, cyclamate, (sodium) saccharin, stevia, and sucralosc.
A pre-encapsulated compound is compound that is prepared to be entrapped inside a fluid matrix or to have a solid coating. Thus, pre- encapsulation provides a firs encapsulation to the compound. Subsequent to that pre-encapsulation the compound may be mixed with other pre-encapsulated or non-encapsulated compounds or remain unmixed. Th pre- encapsulated compound or the mixture of pre-encapsulated and other compounds may undergo a further encapsulation procedure.
Detailed description of the invention
The section headings serve to clarify the subject matter and should not be interpreted to limit the subject matter. If ranges of values are disclosed each individual value Is considered to be covered by d e range, in particular, each integer number. If not noted otherwise, values in % relate to weight/weight (w/w) values.
Pharmaceutical active ingredient
The compositions can comprise a pharmaceutical active ingredient comprising compounds selected from the group consisting of a carminative and an antacid. The composition can comprise 0.05% to 0.3%, 0.10% to 0.20%, 0.125% to 0.175%, or 0. 15% of the pharmaceutical active ingredient. The amount of the carminative in the pharmaceutical ingredient can be 10-90% while the amount o the antacid can be 90-10%. Their combined amounts can make 100% of the pharmaceutical active ingredient. The skilled person based on the nature of the compound can determine any suitable amount for the composition.
The pharmaceutical active ingredient can further comprise a prokinetic agent without altering the total amount of the pharmaceutical active ingredient in die composition. In other words, if a prokinetic agent is comprised in the pharmaceutical active ingredient, the combined amounts of the carminative and the antacid make up for (100% - the amount in % of the prokinetic agent comprised) of the pharmaceutical active ingredient. According to one embodiment, the amount f the carminative in the pharmaceutical ingredient can be 10 80% while the amount of the antacid can be 80-10% and the amount the prokinetic agent can be 80 10. Their combined amounts can make 100% of the pharmaceutical active ingredient. The skilled person based on the nature of the compound can determine any suitable amount f r the composition.
The carminative can be simethicone.
The antacid can be selected from the group of H2-receptor antagonists and proton pump inhibitors. In particular, the antacid can be selected from the group consisting o omeprazole, lansoprazole, dcxlansoprazole, esomeprazole, pantoprazole, rabeprazole, cimetidine, burimamidc, and ranitidine. Particularl preferred is pantoprazole.
The prokinetic agent can be selected from the group consisting of ΜΛ receptor antagonists and 5-1 1T4 antagonists. Preferred prokinetic drugs can be benzamide, cisapride, domperidonc, erythromycin, itopride, mosapride, metoclopramide, prucalopride, renzapride, tcgaserod, or mitemcina!. Particularly preferred is domperidone. Domperidone can also have
antiemetic properties. Thus, the composition can comprise agents with antiemetic properties (antiemetic agents).
Oral contiast agent
Oral contrast agents are agents that can be visualized during dysphagia assessment by image diagnosis such as X-ray or magnetic resonance imaging (Mill). Suitable contrast agents are, depending on the used imaging technique, radio opaque (and therefore suitable for X-ray analysis) and/or can be made visible by magnetic resonance imaging (MRI contrast agents). Radio-opaque contrast agents are salts of iodine or barium. A preferred radio-opaque contrast agent is barium sulphate.
MRI contrast agents are selected from the group consisting of gadolinium chelates, manganese chelates, iron salts, superparamagnetic iron oxide (SPIO), barium sulphate, clay, perflubron, and natural products with high manganese concentration (e.g. blueberry and green tea). Particularly preferred is SPIO.
The compositions can comprise 20· 40%, 25-35%, or 30% of a radio-opaque contrast agent, in particular, barium sulphate. In a preferred embodiment, the radio-opaque contrast agent is pre- encapsula ted.
The compositions can comprise 0.01-0.20, 0.04 -0.1 %, 0.05 0.10% of an MRI contrast agent, in particular, SPIO. In a preferred embodiment, the MRI contrast agent is pre-encapsulated.
Encapsulation
The contrast agents can be pre-encapsulated . The encapsulating agent c n be a gum or a dextrine, in particular, a maltodextrine. Preferable, the barium sulphate is provided in a pre- encapsulated form. Preferably barium sulphate is pre-encapsulated with a gum. MRI contrast agents can be pre-encapsulated with dextrin.
Hydrocolloids
The hydrocolloid or the combination of hydrocolloids can define the iheological properties of the composition.
The hyd ocolloid can be selected from the group of starch, cellulose, methylated cellulose, carboxy-methylated cellulose (CMC), pectin, gum acacia, galactomannan, cambin, aga , carrageen, alginate, gelatin caseinate, xanthan, dextran, scle oglucan, guar, rata, taracanth, karaya gum, locust bean gum or mixtures thereof. The composition can comprise hydrocolloids in an amount of 0.75 -1.75%, 1.0-1.5%, 1.1 -1.4%, 1.2-1.35%, or 1.3%.
Particularly preferred is guar gum. Particularly preferred is guar gum in a range from 0-1.5%, 0.14.5%, 0.2-1.4%, 0.3-1.3%, 0.4-1.2%, 0.5-1.1%, 0.6-1.0%, 0.7- 0.9%, 0.1-0.5%, 0.1-0.4%, 0.1- 0.3%, 0.2-0.35%, 0.3-0.75%, or 0.4-0.6%. An amount of 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.75, or 0,8% of gu r gum is also disclosed.
Also particularly preferred is xanthan gum. Particularly preferred is xanthan gum in a range from 0-1,5%, 0.1-1.5% 0.2-1.4%, 0.3-1.3%, 0.4-1.2%, 0.5-1.1%, 0.6 1.0%, 0.7-0.9%, 0.7-1.3%, 0.8-1.2%, 0.9-1.1%, 0.05-0.4%, 0.1-0.3%, 0.1-0.2%. An amount of 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.75, 0.8%, 0.9%, or 1.0% of xanthan gum is also disclosed.
Furthermore, particularly preferred is methylated cellulose. Particularly preferred is methylated cellulose in a range from 0-1.5%, 0.1-1.5% 0.2-1.4%, 0.3-1.3%, 0.4-1.2%, 0.5- 1.1%, 0.6 1.0%, or 0.7-0.9%. An amount of 0.0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0,75, 0.8% of methylated cellulose is also disclosed.
The preferred methylated cellulose is carboxymcthylat cellulose (CMC).
The composition can also comprise t a gum. The composition can compris tara gum in an amount of 0.0, 0.0 -0.2%, 0.05-0.15%, or 0.1 %.
It is contemplated that every range defined for one radi ocolloid can be combined with every range defined for a second or more hydrocolloids.
Dextrine
The composition can comprise dextrines. The composition can comprise dextrines in an amount of 0.25-1.5%, 0.5-1.25%, 0.75- 1.0%, 0.5, 0.8, or 1.0%. The preferred dextrine is maltodex trin.
Stabilize
Stabilizers can be present in an amount of 0.3-0.5% or 0.4 %. The stabilizer can be selected from the group consisting of polysorbate 80, ceteaiyl alcohol, polysorbate 20, and cetcareth 20. The preferred stabiliser is polysorbate 80.
Flavouring agents can be present in an amount of 0.1-5.0%, 0.1-1.0%, 0.2-0.5%, 0.25-0.35%, or 0.3%. Preferred flavouring agents are cit ic acid, glutamic acid salts, glycine salts, guanylic acid salts, inosinic acid salts, 5'-ribonucleotide salts, acetic acid, ascorbic acid, fumaric acid, lactic acid, malic acid, phosphoric acid, and tartaric acid, or combinations thereof. The preferred flavouring agent is citric acid providing a sour taste.
Suitable flavouring agents ate also those that have the taste of vanilla, strawberry, chocolate, cappuccino, mango, orange, peach, etc., wherein each of them can belong to the group of synthetic, natural- or natural identical flavours.
Polyalcohol
The compositions can comprise pharmaceutical acceptable polyalcohols. The polyalcohols can be present in an amount of 0.5-4.0%, 1 -3.5%, 1.5-3.0%, 1.25-2.5% or 2.0%.
Polyalcohols have the general formula H(HCHO)n+1H. Pharmaceutical acceptable polyalcohols can be selected from the group consisting of glycerol (glycerin), erythrifol, threitol, arabitol, xylitol, ribitol, mannitol, sorbitol, dulcitol, fucitol, iditol, isomalt, maltitol, lactitol, polyglycitol. Polyalcohols comprisin 3 or 4 carbon atoms, in particular, comprising 3 carbon atoms are preferred. Particularly preferred is glycerol.
l'le eiy m es
Preservatives can be present in an amount of 0.0-0.4%, 0.1 - 0.3%, or 0,2%. The preservative can be selected from the group consisting of potassium sorbate, calcium propionate, sodium nitrate, sodium nitrite, and (sodium) benzoatc, or mixtures thereof. Preferred preservatives are potassium sorbate and sodium benzoatc. Preferably, potassium sorbate is present in an amount of 0.1 % and sodium benzoate in an amount of 0.1%
Non-saccharide sweeteners
Non-saccha ide sweeteners can be present in an amount of 0.1-0.3% or 0.2%. The sweeteners ate selected from the group consisting of aspartame, cyclamate, (sodium) saccharin, stcvia, and sucralose. Preferably, the composition contains sodium saccharin.
Nectar and Pudding formulations
A further preferred embodiment relates to formulations having nectar- or pudding like characteristics. These formulations are already disclosed by die combination,? of compounds and ranges described above and are here merely presented for further clarification of the invention.
In particular, the inventions relates to compositions comprising hydrocoUoids that show the same viscosity behavior like nectar and pudding formulations of die prior art (e.g., Varibar Nectar barium Sulfate Suspension and Varibar Pudding Barium Sulfate Esophageal Paste). The claimed formulations show a steady state shear viscosity (η in IVs) in a shear range of
0.001 t 100 (1/s) or 0.01 to 10 (1/s) that is essentially identical to those of nectar and pudding formulations of the prior art. The respective steady state shear viscosity only deviates from the reference formulations by maximally ±10%, ± 1%, ±0.1%, or ±0.01%. Viscous flow
measurements can be carried out in a MARS controlled-stress rheometcr (Thermo -Haakc, Germany) using coaxial- cylinders and plate-and-platc geometries. They can have serrated surfaces, to avoid wall- slip phenomena.
A pudding formulation can comprise 0.0-0.5% or 0.4-0.6% guar gum, 0.8 -1.2% or 1.0% xanthan gum, and 25-35% or 30% barium sulphate, 0.4-0.6% or 0.5% maltodextrin,. A further pudding formulation can comprise 0.0-1.0% guar guam, 1.0-1.5% or 1.25% xanthan gum, 0.5-1.0% CMC, 0.4-0.6% or 0.5% maltodextrin, and 0.05- 0.10% pre-encapsulated
SPIO.
Both pudding formulations can comprise 0.3% citric acid, 2.0% glycerol, 0.4% polysorbate 80, 0.1% potassium sorbate, 0.2% sodium saccharin, 0,1% sodium benzoate, 0.3% sodium citrate, and 0.15% of a pharmaceutical active ingredient comprising a carminative, a prokinetic agent, and an antacid (e.g. simethicone, domperidone, pantobrazole).
nectar formulation can comprise 0.0-0.3% or 0.1-0.2 guar guam, 0.1 0.4% or 0.25% xanthan gum, 0.0-0.1 lata gum and 25-35% or30% barium sulphate, 0.9-1.1%. or 1.0% maltodextrin,. A further nectar formulation can comprise 0.1 -0.5% guar guam, 0.1-0.5% or 0.30% xanthan gum, 0.1 0.5 tara gum, 0.9-1.1 % or 1.0% maltodextrin, and 0.05 0.10% pre- encapsulated SPIO.
Both nectar formulations can comprise 0.3% citric acid, 2.0% glycerol, 0.4% polysorbate 80, 0.1% potassium sorbate, 0.04% sodium saccharin, 0.1% sodium benzoate, 0.3% sodium citrate, nd 0.15% of pharmaceutical active ingredient comprising a carminative, a prokinetic agent, and n antacid (e.g. simethicone, domperidone, pantobrazole).
Met hod of producing liquid compositions
Furthermore, a method for producing liquid compositions of the inventions is provided. The method comprises the steps of providing any f the compounds or a subgroup of the compounds described above, mixing said compounds and thereby producing the composition of the invention. In one embodiment the compounds can be the carminative, the antacid, the oral contrast agent, and the hydrocolloid. The oral contrast agent may be provided in a pre-encapsulated form. Optionally, a further compound may be a prokinetic agent . Optionally, a further compound may be a polyalcohol.
In a further embodiment the water is provided and the compounds are added to the water. Alternatively or in addition, water can be added to the prepared mixture or solution. The obtained solution may be a true solution wherein all compounds are dissolved or alternatively a suspension or dispersion.
In a further embodiment the oral contrast agent is pie encapsulated with a compound (gum, maltodextiin or others) in a watery dispersion (made from purified water) by mixing the encapsulating agent and the oral contrast agent under stirring. Preferentially, barium sulfate is pie-encapsulated with a gum and SPIO is pre-encapsu!ated with a dextrin (e.g. maltodextiin). The stilling speed can be 100 to 500 rpm, 200 to 400 rpm, or 300 tpm. The stirring/incubation time can be 1 to 6 Min, 2 to 4 Min, and preferentially 3 Min yielding a first dispersion. The remaining compounds can be mixed separately by combining water, hydrocolloids (e.g. gums), and other compounds. The mixing occurs under stirring. The stirring speed can be 100 to 500 rpm, 200 to 400 rpm, or 300 rpm. The stirring/incubation time can be 1 to 20 Min, 5 to 15 Min, and preferentially 10 Min yielding a second dispersion. First and second dispersions can be mixed under stirring. The stirring speed can be 500 to 2000 rpm, 750 to 1500 rpm, or 1000 rpm. The stirring/incubation time can be 1 to 60 Min, 15 to 45 Min, and preferentially 30 Min yielding a third dispersion.
In a preferred embodiment the above steps re performed at room temperature. Room temperature can be any value between 20°C-25°C, or 20°C, or 21 °C, or 22° C, or 23°C, 24°C, or 25°C.
In a final step the obtained solution or mixture can be sterilized. The sterilization can be any suitable form of sterilization method suitable for a liquid dispersion like thermal sterilization or sterilization by irradiation. Preferably, the liquid dispersion is thermally sterilized. Conditions for thermally sterilizing a composition are provided in this description.
Method of producing powder compositions
Particularl preferred is to obtain a powder from a liquid dispersion containing pre- encapsulated barium sulphate or SPIO. Moreover, a method for producing a powdered composition of tills invention is provided Phe method comprises the steps of providing any of the compounds or a subgroup of the compounds described above, dry mixing said compounds, then encapsulating the compounds. The compounds of the composition that is prepared by mixing can be one or more hydrocolloids and an oral contrast agent. The composition ca also comprise a compound selected from the group consisting of a carminative, a prokinetic agent an antacid, r mixtures thereof. The composition ca also comprise flavours or polya!cholhols (e.g. glycerol). The mixing can be achieved with the use of a fluidizecl bed and thereby producing the powdered composition of the invention. In one embodiment the compounds can be a carminative, an antacid, a prokinetic agent, an oral contrast agent, and/ or a hydrocolloid.
The oral contrast agent may be provided in a pre- encapsulated fomi. Th oral contrast agent can be pre-encapsulated with a compound (g m, maltodextrin or others) in a watery dispersion (made from purified water) by mixing the pre- encapsulating agent and the oral contrast agent under stirring. Preferentially, barium sul ate is pre-encapsulated with a gum and SPIO is pre-encapsulated with a dextrin (e.g. maltodextrin). The stirring speed can be 100 to 500 rpm, 200 to 400 rpm, or 300 rpm. The stirring/incubation time can be 1 to 6 Min, 2 to 4 Min, and preferentially 3 Min yielding a dispersion. Then the obtained dispersion is dried to yield a powdered form of the pre-encapsulated contrast agent and is ready for use in the above described dry mixing method.
The powder composition obtainable by the above method contains all non-liquid compounds that are required for preparing a composition for dysphagia assessment. Only water needs to be added to reconstitute a dispersion.
Imaging Method
A method for imaging the swallowing of a liquid by a subject by an x-ray or MRI imaging system is provided. The method comprises recording the x-ra or Mill signals emitted from a subject swallowing a liquid preparation of the compositions provided in this description and imaging the x-ray or MRI signals. In the case o x- ray imaging the subject can be exposed to x-rays when the x-ray images ate recorded. Methods for recording x-ray or MRI signals are known in the art. However, the liquid compositions disclosed in this description are different from the liquid compositions of the prior art.
In addition, a method for diagnosing dysphagia is disclosed. Hie method comprises the imagin steps defined above followed by a diagnostic phase where it is analysed whether the subject exhibits signs of dysphagia. The analysis can be performed by visual inspection by a skilled practitioner or by an automated method, for example, assisted by a computer program.
The i f value o the solution can be between 3 and 6, between 4 and 5, between 4.3 and 4.6, or can be 4.4 or 4.5.
Sterilization
The compositions of the invention can be thermally sterilized (at a temperature that is above room temperature, i.e. above 25 C). Preferably, the sterilization is performed above 100°C, more preferably 105 und 150°C, in particular, between 110 und 130°C, or at 121°C. The length of the period at elevated temperature can be from 2 seconds up to 30 min., up to 25 min., in particular, between 10 min. and 20 min., or be 15 min.
The sterilization can be performed at regular atmospheric pressure (1.0 bar) or at elevated pressure (1.8 to 2.0 bar).
Administration /dosage
The liquid compositions can be provided as ready-to-use compositions in containers of 150 ml, 200 ml, 250 ml, or 300 ml size or as powders to be reconstituted by adding the necessary amount of water to produce, for instance, nectar-like or pudding like compositions compositions in containers of 50 ml, 200 ml, 250 ml, or 300 ml size. The patient is positioned laterally before a suitable x-ray or Mill device and asked to swallow one of the compositions. A suitable recording equipment is then used to visualize and record the passage of the composition through the mouth and throat down to the esophagus during swallowing.
Advantages
The invention has several advantages over the swallow test feeds f the prior art. In particular, the unique combination o hydro colloids allows to better simulate the theological behavior of nectar and pudding like compositions.
The claimed compositions contain in some embodiments a carminative, a prokinetic agent, and an antacid (for example, simethicone, domperidone, and pantoprazole), a combination that has not been used before fo dysphagia assessment. This mixture has been used aiming to avoid/prevent the negative effects of oral contrast media, in particular, barium sulphate on the patient. Barium sulphate causes nausea, vomiting, diarrhea, constipation, abdominal pain, etc. These active ingredients do not modify the performance of these contrast media but do improve patient's quality of life after dysphagia diagnosis tests. The chosen combination has been found to be particularly beneficial for the patients' well-being fter swallowing a composition containing an oral contrast agent.
The flavouring of the formulations allows a better compliance. Thus, the formulations provided by the invention are more likely to be accepted by the patient.
The use of glycerol can enhance the suspension stability and favours hydrocolloid dispersion, thereby avoiding the formation of aggregates and preventing phase separation.
In particular embodiments, the radio opaque, contrast agent (e.g. barium sulphate) is pre- encapsulated . It has been surprisingly found that the barium sulphate pre-cncapsulation contributes to a decrease, in barium sulphate adhesion to the stomach and intestinal walls. Further more, it has been found that with respect to barium sulphat the pre-encapsulation improves suspension stability, improves organoleptic properties, improves particle size
distribution, decreases barium sulphate adhesion to the stomach and intestinal walls. In addition, it has been found that the pie-encapsulation of SPIO improves iron particle stability, avoids agglomeration, and favors diagnosis by MRI.
A powder can be prepared from a composition having the radio opaque contrast agent in p e-encapsulated form which allows easier handling, storage and shelf life of the composition. The powder may comprise any of the powdery compounds described in the detailed description.
All manufacturing steps can be performed at room temperature thereby simplifying the production method and associated costs.
Furthermore, this liquid formulation can be submitted to thermal sterilization in a final preparative step- Finally, this is the first time SPIO is used for dysphagia assessment. Presently, there are no contrast media for dysphagia assessment available containing superparamagnetic iron oxide in the market. Barium sulphate is the "standard" contrast agent for dysphagia assessment. However, barium sulphate cannot be metabolised by the human body. Thus, it has been reported that barium sulphate can adhere to the gastrointestinal tract which can have a negative effect on the patient. On the. contrary, iron diffuses to the blood stream, being its excess metabolised and eliminated by macrophages, spleen, liver and faeces. Thus, the use of Mill contrast agents has advantages.
Examples
Example 1: Exemplary compositions comprising supetpaiamagnetic iron oxide
Table 1
Table 2
AGENTS, ANTACIDS
(SIMETHICONE, DOMPERIDONE,
PANTOPRAZOLE)
FLAVOURS (vanilla, strawberry) 0-5.0
PURIFIED WATER Up to 100%
Example 2: Exemplary compositions comprising barium sulphate The formulations were produced according to following scheme:
Dispersions A and B were prepared separately and then mixed. The obtained mixture was treated with an agitator (IKA T50 basic) as indicated above yielding a dispersion C. Finally the dispersion was subjected to sterilization.
Table 3
CITRIC ACID 0.3
GLYCERIN 2.0
MALTODEXTRIN 0.5
POLYSORBATE 80 0.4
POTASSIUM SORBATE 0.1
SODIUM SACCHARIN 0.2
SODIUM ΒΕΝΖΟΑΊΈ 0.1
SODIUM CITRATE 0.3
ANTIEMETICS AND 0.15
ANTIACIDS
(SIMETHICONE,
D OMPERID ONE,
ANTO PR AZO L E)
FLAVOURS (vanilla, 0-5.0
strawberry)
PURIFIED WATER Up to 100%
Tabic 4
The following three compositions A-C were prepared.
Table 5
Nectar formulation
Ingredient Composition
A B C
XANTHAN GUM 0.3 0.35 0.4
OTHER INGREDIENTS Up to 100% Up to 100% Up to 100%
The viscosities of these fluids (η in IVs) were measured in relation to t e shear rate (γ in s"1) using a rheometer equipped with, a serrated plate-plate geometry at 25°C. The control nectar was Varibar Nectar Barium Sulfate Suspension (Ezcm, Canada). As can be observed in Fig. 1 the formulations show the flow behavior o control nectar.
The following four compositions I IV were prepared.
Table 6
The viscosities of these fluids (n in IVs) were measured in relation to the shear rate (γ in s ') as above at 25°C. The control nectar was Varibar Nectar Barium Sulfate Suspension (Ezem, Canada). As can be observed in Fig. 2, the viscous behavior of these 4 compositions matches the flow behavior of die control nectar.
The following diree compositions A-C were prepared.
Table 7
The viscosities of these fluids (η in Pa's) were measured in relation to the shear rate ( in s"1) as above at 25°C. The control pudding was V atibat Pudding Barium Sulfate Esophageal Paste (Ezem, Canada). As can be observed in Fig. 3, only composition A matches die flow behavior of the control pudding.
The following compositions 1-lV were prepared. Table 8
Pudding formulation
The viscosities of these fluids (η in IVs) were measured in relation to the sheaf rate (γ in s"1) as above at 25°C. The control pudding was Vaiibar Pudding Barium Sulfate Esophageal Paste (Ezem, Canada). As can be observed Fig. 4, only the composition II does not match the flow behavior of the control pudding.
Claims
1. Composition suitable, for dysphagia assessment by image diagnosis comprising an oral contrast agent, a carminative, a prokinetic agent, an antacid, and a hydrocol!oid.
2. Composition according to claim 1 wherein the carminative is simethicone.
3. Composition according to any of the above claims wherein the prokinetic agent is selected from the group of domperidone, benzamide, cisapride, erythromycin, itopridc, niosapiide, metocloptamide, p) ucalopiide, renzapride, tegaserod, and mitemcinal.
4. Composition according to any of the above claims wherein the antacid is selected from the group of patitoprazole, omeprazole, lansoprazole, dexlansoprazole, esomeprazole, labeprazole, cimetidine, and burimamide.
5. Composition according to any of the above claims wherein the oral contrast agent is selected from the group of radio-opaque and contrast agents suitable for magnetic resonance imaging.
6. Composition according to any o the above claims wherein the oral contrast agent is a radio- opaque agent selected from the group consisting of barium sulphate and iodine.
7. Composition accordin to any of the above claims wherein the oral contrast agent is contrast agent suitable for magnetic resonance imaging and is selected from the group consisting of superparamagnetic iron oxide (SPIO), gadolinium chelates, manganese chelates, iron salts, barium sulphate, clay, perflubron, and natural products with high manganese concentration.
8. Composition according to the above claims wherein the oral cont ast agent has a pharmaceutical acceptable encapsulating agent.
9. Composition according to any of the above claims wherein the hydrocolloid is selected from the group of starch, cellulose, methylated cellulose, pectin, gum acacia, galactomannan, carubin, agar, carrageen, alginate, gelatin caseinate, xanthan, de.xti.an, scleroglucan, guar, tara or combinations thereof.
10. Composition according to any the above claims further comprising a polyalcohol wherein the polyalcohol is selected from the group of glycerol, glycol, erythritol, threitol, tabito!, xylttol, ribitol, mannitol, sorbitol, dulcitol, fucitol, iditol, isomalt, maldtol, lactifol, and polyglycitoi or combinations thereof.
11. Composition according to any of the above claims further comprising one or more compounds selected from the group consisting of flavoring agents, dextrines, stabilisers, non-saccharide sweeteners, and preservatives or combinations thereof.
12. Composition suitable for the preparation o a composition for dysphagia assessment b image diagnosis comprising a guar gum in an amount of 0-0.5%, xanthan gum in an amount of 0.1% 1.5%, tara gum in an amount of 0.0-0.1%, carboxy-methyl cellulose in an amount of 0.0 1.0%, maltodextrin in an amount of 0.5-1.0%, optionally containing an oral contrast agent, a carminative, a prokinetic agent, an antacid, a flavorin agents, dextrine, stabilisers, non-saccharide sweeteners, and/or preservatives.
13. A powdered preparat ion comprising the composition of any of die above claims.
14. A liquid preparation comprising the composition of any of the above claims.
15. A method for producing a composition of claims 1-12 comprising
a. Providing the compounds of claims 1 -12
b. Mixing said compounds
thereby producing die composition of any of claims 1 12.
16. A method for producing the liquid preparation of claim 14, comprising the steps of claim 15, further comprising adding water to the compounds of claims 1-12, thereby dispersing the compounds in said water
wherein said water is added in a step prior to step a, pre- a., or in a step following step b., step c.
17. The method of claims 15 or 16 wherein the method is performed at room temperature.
18. The method of claim 17 further comprising the sterilization of the obtained mixture or dispersion
1 . A method for imaging the swallowing of a liquid by a subject by an x- ray or MRI imaging system comprising
a. recording the x-ra or MRI signals emitted from a subject swallowing the liquid preparation of claim 14
b. imaging the x-ray or MRI signals.
20. The method of claim 19 wherein the liquid preparation comprises SPIO and an MRI imaging system is used.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13708838.1A EP2825064A1 (en) | 2012-03-15 | 2013-03-13 | Compositions for dysphagia assessment |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261611053P | 2012-03-15 | 2012-03-15 | |
US61/611,053 | 2012-03-15 | ||
EP12159590 | 2012-03-15 | ||
EP12159590.4 | 2012-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013135737A1 true WO2013135737A1 (en) | 2013-09-19 |
Family
ID=49160278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2013/055064 WO2013135737A1 (en) | 2012-03-15 | 2013-03-13 | Compositions for dysphagia assessment |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2825064A1 (en) |
WO (1) | WO2013135737A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014064154A1 (en) * | 2012-10-26 | 2014-05-01 | Fresenius Kabi Deutschland Gmbh | System for use in dysphagia diagnosis |
CN108517201A (en) * | 2018-03-28 | 2018-09-11 | 方建波 | A kind of preparation method of the high compound tackifier of anticalcium type |
WO2019064104A1 (en) * | 2017-09-27 | 2019-04-04 | Perrenoud Nicolas | Composition for food texturisation |
CN113950255A (en) * | 2019-03-22 | 2022-01-18 | 杜邦营养生物科学有限公司 | Method for preparing easily dispersible hydrocolloid composition |
Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB478108A (en) * | 1936-05-15 | 1938-01-12 | Schering Kahlbaum Ag | Improvements in or relating to x-ray contrast media |
GB708096A (en) * | 1951-03-22 | 1954-04-28 | Byk Gulden Lomberg Chem Fab | Improvements in or relating to x-ray contrast agents |
GB1493974A (en) * | 1974-03-14 | 1977-12-07 | Pharmacia Ab | X-ray contrast preparation |
GB1542677A (en) * | 1975-02-05 | 1979-03-21 | Schering Ag | Oral x-ray contrast preparations |
WO1994004037A1 (en) * | 1992-08-21 | 1994-03-03 | Unilever N.V. | Bakery custard |
EP0620012A1 (en) * | 1992-10-02 | 1994-10-19 | Ohta Seiyaku Kabushiki Kaisha | X-ray contrast medium for examining large and small intestines |
EP1046347A1 (en) * | 1998-01-08 | 2000-10-25 | Otsuka Foods Co., Ltd. | Gelled foods and process for producing the same |
WO2001015743A2 (en) * | 1999-08-27 | 2001-03-08 | Wisconsin Alumni Research Foundation | Viscosity-standardised compositions which facilitate swallowing in dysphagic subjects |
EP1252884A2 (en) * | 2001-04-26 | 2002-10-30 | Thomas Gieselmann | Oral composition for human or veterinairy medicine |
US20040092511A1 (en) * | 1999-12-10 | 2004-05-13 | Billstein Stephan Anthony | Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders |
WO2005007600A2 (en) * | 2003-07-11 | 2005-01-27 | Eisai Co., Ltd. | Novel methods using aminobenzoic acid compounds |
WO2005041677A1 (en) * | 2003-10-30 | 2005-05-12 | Arla Foods Amba | Stabilisers useful in low fat spread production |
WO2007093293A1 (en) * | 2006-02-13 | 2007-08-23 | Sweetwell Nv | Functional sugar replacement |
WO2007095871A2 (en) * | 2006-02-24 | 2007-08-30 | Ustav Makromolekularni Chemie Akademie Vedceske Republiky, V.V.I | Superparamagnetic nanoparticles based on iron oxides with modified surface, method of their preparation and application |
US20080160133A1 (en) * | 2006-12-27 | 2008-07-03 | Kraft Food Holdings, Inc. | Low Fat, Whey-Based Cream Cheese Product With Carbohydrate-Based Texturizing System and Methods of Manufacture |
EP1987724A1 (en) * | 2006-02-01 | 2008-11-05 | Hiroshima Prefecture | Food and process for producing food |
WO2008144259A1 (en) * | 2007-05-18 | 2008-11-27 | The Coca-Cola Company | Beverages comprising a rice extract, derivatives thereof, or combinations thereof |
US20090047220A1 (en) * | 2007-08-13 | 2009-02-19 | Hon Hai Precision Industry Co., Ltd. | Contrast medium for administration to a patient for magnetic resonance imaging |
WO2009134929A2 (en) * | 2008-05-01 | 2009-11-05 | Revalesio Corporation | Compositions and methods for treating digestive disorders |
US20110097267A1 (en) * | 2005-12-21 | 2011-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions for imaging pain and stress in vivo |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5976084A (en) * | 1997-10-24 | 1999-11-02 | Regents Of The University Of Minnesota | Standardized test for dysphagia |
-
2013
- 2013-03-13 WO PCT/EP2013/055064 patent/WO2013135737A1/en active Application Filing
- 2013-03-13 EP EP13708838.1A patent/EP2825064A1/en not_active Withdrawn
Patent Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB478108A (en) * | 1936-05-15 | 1938-01-12 | Schering Kahlbaum Ag | Improvements in or relating to x-ray contrast media |
GB708096A (en) * | 1951-03-22 | 1954-04-28 | Byk Gulden Lomberg Chem Fab | Improvements in or relating to x-ray contrast agents |
GB1493974A (en) * | 1974-03-14 | 1977-12-07 | Pharmacia Ab | X-ray contrast preparation |
GB1542677A (en) * | 1975-02-05 | 1979-03-21 | Schering Ag | Oral x-ray contrast preparations |
WO1994004037A1 (en) * | 1992-08-21 | 1994-03-03 | Unilever N.V. | Bakery custard |
EP0620012A1 (en) * | 1992-10-02 | 1994-10-19 | Ohta Seiyaku Kabushiki Kaisha | X-ray contrast medium for examining large and small intestines |
EP1046347A1 (en) * | 1998-01-08 | 2000-10-25 | Otsuka Foods Co., Ltd. | Gelled foods and process for producing the same |
WO2001015743A2 (en) * | 1999-08-27 | 2001-03-08 | Wisconsin Alumni Research Foundation | Viscosity-standardised compositions which facilitate swallowing in dysphagic subjects |
US20040092511A1 (en) * | 1999-12-10 | 2004-05-13 | Billstein Stephan Anthony | Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders |
EP1252884A2 (en) * | 2001-04-26 | 2002-10-30 | Thomas Gieselmann | Oral composition for human or veterinairy medicine |
WO2005007600A2 (en) * | 2003-07-11 | 2005-01-27 | Eisai Co., Ltd. | Novel methods using aminobenzoic acid compounds |
WO2005041677A1 (en) * | 2003-10-30 | 2005-05-12 | Arla Foods Amba | Stabilisers useful in low fat spread production |
US20110097267A1 (en) * | 2005-12-21 | 2011-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions for imaging pain and stress in vivo |
EP1987724A1 (en) * | 2006-02-01 | 2008-11-05 | Hiroshima Prefecture | Food and process for producing food |
WO2007093293A1 (en) * | 2006-02-13 | 2007-08-23 | Sweetwell Nv | Functional sugar replacement |
WO2007095871A2 (en) * | 2006-02-24 | 2007-08-30 | Ustav Makromolekularni Chemie Akademie Vedceske Republiky, V.V.I | Superparamagnetic nanoparticles based on iron oxides with modified surface, method of their preparation and application |
US20080160133A1 (en) * | 2006-12-27 | 2008-07-03 | Kraft Food Holdings, Inc. | Low Fat, Whey-Based Cream Cheese Product With Carbohydrate-Based Texturizing System and Methods of Manufacture |
WO2008144259A1 (en) * | 2007-05-18 | 2008-11-27 | The Coca-Cola Company | Beverages comprising a rice extract, derivatives thereof, or combinations thereof |
US20090047220A1 (en) * | 2007-08-13 | 2009-02-19 | Hon Hai Precision Industry Co., Ltd. | Contrast medium for administration to a patient for magnetic resonance imaging |
WO2009134929A2 (en) * | 2008-05-01 | 2009-11-05 | Revalesio Corporation | Compositions and methods for treating digestive disorders |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014064154A1 (en) * | 2012-10-26 | 2014-05-01 | Fresenius Kabi Deutschland Gmbh | System for use in dysphagia diagnosis |
WO2019064104A1 (en) * | 2017-09-27 | 2019-04-04 | Perrenoud Nicolas | Composition for food texturisation |
CN108517201A (en) * | 2018-03-28 | 2018-09-11 | 方建波 | A kind of preparation method of the high compound tackifier of anticalcium type |
CN113950255A (en) * | 2019-03-22 | 2022-01-18 | 杜邦营养生物科学有限公司 | Method for preparing easily dispersible hydrocolloid composition |
EP3941218A4 (en) * | 2019-03-22 | 2022-11-30 | DuPont Nutrition Biosciences ApS | A process for preparing a readily dispersible hydrocolloid composition |
Also Published As
Publication number | Publication date |
---|---|
EP2825064A1 (en) | 2015-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5940118B2 (en) | Emulsified food composition | |
KR100569488B1 (en) | Multilayered soft capsule for eliminating foul breath and process for producing the same | |
KR101384425B1 (en) | Gel type enteric nutrient | |
JP5541865B2 (en) | Gelling composition and method | |
TWI405587B (en) | Medicinal granulated jelly drink and preparation method thereof | |
JP5048398B2 (en) | Pharmaceutical composition of antifungal agent | |
EP1621080A1 (en) | Edible film compositions | |
WO2013135737A1 (en) | Compositions for dysphagia assessment | |
JP4264105B2 (en) | Isosorbide-containing jelly preparation | |
CN109123630A (en) | Has effects that nutraceutical of assisting deglutition and preparation method thereof | |
WO2010050541A1 (en) | Food for people having difficulty chewing and/or swallowing | |
CN101721931A (en) | Multi-phase suspension system, preparation method and application thereof | |
JP6627485B2 (en) | Gel composition and method for producing the same | |
JP6134156B2 (en) | Antidiarrheal composition | |
CN107115534A (en) | A kind of intestines and stomach diagnostic imaging imaging assistant and preparation method thereof | |
KR102314879B1 (en) | Drinking jelly composition comprising Psyllium husk | |
JP2008528583A (en) | Azithromycin powder composition for oral suspension | |
KR101486534B1 (en) | Oral preparation and preparation method of the same | |
JP4870957B2 (en) | Gelled food for liquid nutritional food | |
TW201410256A (en) | Examining material of ingestion swallowing function | |
JP6029874B2 (en) | Sol pharmaceutical composition containing itraconazole | |
JP2018102265A (en) | Food composition for person having difficulty in chewing/swallowing | |
JP6950312B2 (en) | Liquid pharmaceutical compositions and pharmaceuticals | |
US20230136537A1 (en) | Simethicone chewable composition | |
WO2024042123A1 (en) | Dietary supplements comprising silica particles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13708838 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013708838 Country of ref document: EP |